Earnings ·
AchieveRx reports Q3 net loss of $12.1M; cash rises to $201.5M on warrant exercise proceeds
ACHVAchieve Life Sciences, Inc.
AchieveRx reported a third-quarter 2026 net loss of $12.1 million, or $0.11 per share, compared to a $14.4 million loss in the prior-year period. The quarter included a non-cash gain of $6.9 million from the change in fair value of warrant liabilities. Total operating expenses increased to $20.5 million as the company transitioned toward commercialization. Cash, cash equivalents, and marketable securities rose to $201.5 million from $187.3 million at June 30, primarily due to proceeds from the exercise of previously issued warrants. The company also announced a new corporate brand identity as AchieveRx, The Quit Company, and completed three commercial-scale stability batches for its investigational smoking cessation drug cytisinicline. NDA resubmission remains on track for the fourth quarter of 2026.